Baidu
map

神经科

订阅

MedSci主页 / 所有栏目 / 神经科

NRR：高尔基体阻断剂是治疗脑梗死的新希望

2013-09-05 伊文 EurekAlert中文版

高尔基体阻断剂脑梗死
关注

　　研究发现在脑梗死常见危险因素中，多伴有患者血清sCD40L水平增高。血中sCD40L约95%来自活化血小板，但目前CD40L由血小板内转移至胞膜并释放的具体途径还不清楚。高尔基体是否参与了血小板CD40L的表达尚需证实。中南大学湘雅二医院卢伟博士及其同事的一项研究发现：急性脑梗死后血小板高尔基体的形态变化与血小板活化后合成和分泌功能增强有关。高尔基体可能参与了血小板CD40L的合成和转

研究发现在脑梗死常见危险因素中，多伴有患者血清sCD40L水平增高。血中sCD40L约95%来自活化血小板，但目前CD40L由血小板内转移至胞膜并释放的具体途径还不清楚。高尔基体是否参与了血小板CD40L的表达尚需证实。中南大学湘雅二医院卢伟博士及其同事的一项研究发现：急性脑梗死后血小板高尔基体的形态变化与血小板活化后合成和分泌功能增强有关。高尔基体可能参与了血小板CD40L的合成和转运，应用高尔基体阻断剂减少血小板CD40L表达可能成为治疗急性脑梗死的新靶点。相关内容发表于《中国神经再生研究（英文版）》杂志于2013年8月23期。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1709977, encodeId=ef301e0997743, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Tue Dec 03 01:51:00 CST 2013, time=2013-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816414, encodeId=11aa1816414ec, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Wed Apr 09 00:51:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969896, encodeId=9971196989601, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Wed Oct 09 19:51:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465046, encodeId=5e781465046fe, content=<a href='/topic/show?id=2dea8489010' target=_blank style='color:#2F92EE;'>#脑梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84890, encryptionId=2dea8489010, topicName=脑梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccf56689148, createdName=karmond, createdTime=Sat Sep 07 04:51:00 CST 2013, time=2013-09-07, status=1, ipAttribution=)]
    2013-12-03 41514497@qq.com

    #阻断#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1709977, encodeId=ef301e0997743, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Tue Dec 03 01:51:00 CST 2013, time=2013-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816414, encodeId=11aa1816414ec, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Wed Apr 09 00:51:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969896, encodeId=9971196989601, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Wed Oct 09 19:51:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465046, encodeId=5e781465046fe, content=<a href='/topic/show?id=2dea8489010' target=_blank style='color:#2F92EE;'>#脑梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84890, encryptionId=2dea8489010, topicName=脑梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccf56689148, createdName=karmond, createdTime=Sat Sep 07 04:51:00 CST 2013, time=2013-09-07, status=1, ipAttribution=)]
    2014-04-09 12498ca5m83暂无昵称

    #阻断剂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1709977, encodeId=ef301e0997743, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Tue Dec 03 01:51:00 CST 2013, time=2013-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816414, encodeId=11aa1816414ec, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Wed Apr 09 00:51:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969896, encodeId=9971196989601, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Wed Oct 09 19:51:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465046, encodeId=5e781465046fe, content=<a href='/topic/show?id=2dea8489010' target=_blank style='color:#2F92EE;'>#脑梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84890, encryptionId=2dea8489010, topicName=脑梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccf56689148, createdName=karmond, createdTime=Sat Sep 07 04:51:00 CST 2013, time=2013-09-07, status=1, ipAttribution=)]
    2013-10-09 珙桐

    #新希望#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1709977, encodeId=ef301e0997743, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Tue Dec 03 01:51:00 CST 2013, time=2013-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816414, encodeId=11aa1816414ec, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Wed Apr 09 00:51:00 CST 2014, time=2014-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969896, encodeId=9971196989601, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Wed Oct 09 19:51:00 CST 2013, time=2013-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465046, encodeId=5e781465046fe, content=<a href='/topic/show?id=2dea8489010' target=_blank style='color:#2F92EE;'>#脑梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84890, encryptionId=2dea8489010, topicName=脑梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccf56689148, createdName=karmond, createdTime=Sat Sep 07 04:51:00 CST 2013, time=2013-09-07, status=1, ipAttribution=)]
    2013-09-07 karmond

    #脑梗#

    0

Baidu
map
Baidu
map
Baidu
map